Skip to main content

Table 1 Demographics and disease characteristics of included patients (n = 198)

From: Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis

 No. with available dataIncluded patients (n = 198)
Demographics
 Sex, female, no. (%)198145 (73.2)
 Ethnicity, no. (%)
  White161140 (87.0)
  Black16116 (9.9)
  Asian1615 (3.1)
 Age, mean ± SD, years19851.1 ± 14.3
Diseases characteristics
 Autoantibody status a, no. (%)
  Anti-nuclear antibody positive165156 (94.5)
  Anti-centromere15243 (28.3)
  Anti-topoisomerase15285 (55.9)
  Anti-RNAP31528 (5.3)
  Anti-U1 RNP1529 (5.9)
  Anti-PM/Scl1526 (4.0)
 Disease duration, median (IQR), years1980.8 (0.4; 1.2)
 Duration from RP, median (IQR), years1871.3 (0.6; 3.9)
 Follow-up, median (IQR), years1986.3 (3.8; 8.9)
Skin variables
 Cutaneous subset, limited, no. (%)19598 (50.3)
 mRSS, baseline, median (IQR)1988 (2; 18)
Baseline organ involvement, no. (%)
 Telangiectasia18376 (41.5)
 Calcinosis17520 (11.4)
 Joints191114 (59.7)
 Muscles19453 (27.3)
 Digital ulcers18176 (42.0)
 Gastrointestinal tracts18799 (52.9)
 Interstitial lung disease18172 (39.8)
 FVC, median % (IQR)16096.0 (76.0; 108.0)
 DLCO, median % (IQR)15563.0 (50.0; 78.0)
 Heart18715 (8.0)
 Pulmonary hypertension19415 (7.7)
 Renal crisis12312 (9.8)
Biological variable, no. (%)
 Baseline CRP level, ≥ 6 mg/L14851 (34.5)
Treatments b, no. (%)
 Steroids and/or IS189127 (68.7)
  1. Numbers are given as % or mean ± standard deviation (SD) or median with interquartile range. Anti-RNAP3 anti-RNA polymerase III antibodies, CRP C-reactive protein; disease duration duration from the first non-RP symptom, DLCO diffusing capacity of the lung for carbon monoxide (% predicted value), FVC forced vital capacity (% predicted value), RP Raynaud’s phenomenon
  2. aThe sum of % may be different from 100% because some patients had either unidentified ANA or multiple autoantibodies
  3. bDuring follow-up
\